Passions

Traveling

Time with family

Scuba diving

Drones

Experience

Cooley advises Provivi on $45.5M Series C-2 Round

January 8, 2021

Cooley advised emerging crop protection company Provivi on its $45.5 million series C-2 financing round led by Vivo Capital, with participation from returning shareholders. Provivi has developed a truly disruptive technological platform that enables the scalable production of environmentally friendly insect pheromone products. These products are able to naturally disrupt the mating cycle of insect pests and reduce the current overreliance upon non-sustainable synthetic insecticides. "The Series C-2 financing is a new milestone in the growth of our company. It builds upon a very successful year where Provivi achieved several product registrations worldwide and launched our first product commercially in Mexico," said Dr. Pedro Coelho, cofounder and CEO of Provivi.

Related contacts

Chris Holly
Partner, Washington DC
Rachel Proffitt
Partner, San Francisco
Rachel M. Burns
Associate, San Francisco
Julia Gage
Associate, San Francisco
Ron Metzger
Paralegal Specialist, San Francisco
Marcelo Pomeranz
Associate, San Diego

Cooley secures key patent on agricultural disease-fighting bacterium for Montana State University's College of Agriculture

December 13, 2018

The patented process uses a naturally occurring BmJ bacterium to activate the natural immune defenses of plants against bacterial, viral, and fungal diseases. The BmJ bacterium was originally isolated from the healthy leaves of beet plants in an otherwise disease-ridden sugar beet field. Dr. Barry Jacobsen, a professor of plant sciences and plant pathology, discovered BmJ's role in natural plant resistance, and played a key role in developing the bacterium into a commercial product.

This novel treatment is expected to provide farmers with an effective and natural alternative to traditional chemical crop treatments. The patented BmJ spray was recently approved by the EPA for use in the United States, and is expected to become available soon to farmers all over the world through MSU's partnership with Certis USA.

Cooley attorneys were instrumental in counseling MSU throughout the patent procurement and licensing phases of BmJ's development. Cooley is now home to the largest life sciences patent practice in the US, and is a leader in working with universities, as well as startup and established companies in developing next-generation Ag-Biotech solutions

Related contacts

Chris Holly
Partner, Washington DC
Marcelo Pomeranz
Associate, San Diego

Cooley advises Zymergen on patent matters surrounding $400 million landmark agtech deal

February 22, 2016

Cooley advised Zymergen on patent prosecution and IP diligence matters surrounding its $400 million Series C funding which closed in December 2018 and was led by returning investor SoftBank Vision Fund. The deal is the largest round of funding for a US-based startup operating upstream in the food and agriculture supply chain. Cooley lawyers Erich Veitenheimer and Chris Holly headed the team advising Zymergen.

Zymergen is the world’s first molecular manufacturing technology company, developing molecules used in industries including agriculture, chemicals, materials, pharmaceuticals, electronics and more.

Cooley’s patent team advises Zymergen on all aspects of IP matters, including the company’s foundational high-throughput genomic engineering platform.

Related contacts

Chris Holly
Partner, Washington DC
Marcelo Pomeranz
Associate, San Diego
Catherine Cowley
Special Counsel, London
Jong-Jin (JJ) Han
Patent Agent, Washington DC
Michael McEvoy
Patent Agent, Washington DC
Jordan Phelan
Associate, Washington DC
Jeffery Wyzykowski
Patent Agent, Washington DC